Continued">Continued">Continued">11q aberrations – Children Cancer Hospital Egypt 57357
  • 19057

11q aberrations

  • Clinical Implications
    • Diagnosis of Burkitt-like (BLL) lymphoma with 11q aberration

      • BLL-11q: initially recognized as a particular subset of HGBCL that had an expression profile and some pathological characteristics similar to those of Burkitt lymphoma but lacked MYC-translocations & alternatively shared a common pattern of 11q23 gains & 11q24- qter loss.

  • Test Description

    • Real-Time Polymerase Chain Reaction (qPCR).

  • Reporting name

    • 11q23 & 11q24 Aberration Analysis

  • Test prerequisites (To ensure timely results)
    • Patient’s demographic data.
    • Clinicopathologic information:
      • Pathology report (final or preliminary) including anatomic location.
      • History of any given therapy for cancer and its date and relation to sample sent for molecular study (i.e. pre & post therapy). Therapy includes chemo and radiotherapy, hormonal or targeted therapy.
      • Any other relevant clinical data or history.
    • Type of sample:
      • Preferred: Formalin-fixed, paraffin-embedded (FFPE) tumor tissue block.
      • Acceptable:
        • Section in Eppendorf: Up to 4 sections, each with a thickness of up to 10 μm and a surface area of up to 250 mm2 + good H&E slide for assessment.
        • Five unstained slides + one good H&E slide.
      • Specimen Minimum Volume: Two 10-micron sections of FFPE
  • Quality Control measures

    • All samples are subject to stringent quality control measures that include:

  • From your side:
    • Double check you are fulfilling all required data before sending your sample.
    • Check that your pathologist has selected the best block in terms of tumor cellularity, with least presence of necrosis and inflammation.
    • Pretherapy sample is preferred (if underwent any cancer therapy).
  • In our lab:
    • Assessment of tissue for adequacy & tumor cellularity before any molecular analysis.
    • Matching block ID with the report ID and demographic data.
    • Matching the submitted block with the data reported in the pathology report.
  • N.B.
    • If the sample sent in Eppendorf, it is your pathology lab’s responsibility to ensure the sample in Eppendorf is corresponding to the submitted H&E slide (we can’t prepare slide from Eppendorf).
    • This test does not include a pathology consultation.
  • Test Time

    • From 3 days to 5 working days.

  • Retention of the sample

    • Client provided paraffin blocks, Whole Blood EDTA and unstained slides (if provided) will be returned after testing is complete.

  • Selected References
    1. Salaverria I et al: A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 123(8):1187-98, 2014
    2. Gonzalez-Farre B, et al; Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica. 2019;104(9):1822-1829, 2018